As market demand continues to rise for more potent and effective therapeutics, biologic pipelines are evolving from standard antibody formats to next-generation biologics (NGBs). There is a real need for robust and scalable expression platforms that can keep pace with this shift towards more complex protein formats, which can prove challenging for traditional expression systems.
In this webinar, we will discuss and demonstrate application through case studies, two significant enhancements to Lonza’s GS Xceed® expression system to help address the challenges of NGBs.
